Get started

Pharmaceuticals

Teva Pharmaceutical industries. up or down? This is my first wave chart, so be gentle. :) i have 2 scenario. One is that wave 5 have ended and we are ready to a correctional wave of A,B,C. The other is that they will present bad revenue. And the price will continue the down trend, and stop at the support line at 6,49 where the 5th wave could end and start a correction of A,B,C. Fundamental: Teva have a great product portfolio, but have lost 64.46% decline year to date. and a 68.83% decline from 30/10/2016 to 30/10/2017 The decline have something to do with there stock pilling on debt that run along the loss in product sales. The U.S. generics industry is facing significant competitive and pricing pressure, which have been affecting the company’s generic revenues. An increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry. earlier this month, in a major blow to Teva, Mylan MYL launched its generic version of the 40 mg formulation, much earlier than expected. Mylan also launched a second generic version of Copaxone 20 mg formulation (once-daily). Though these generic launches will not hurt Teva’s third-quarter sales and profits, Teva estimates that it will have a negative impact of at least 25 cents per share on fourth-quarter earnings. Teva Pharmaceutical industries have a P/E Ratio (TTM)=-2,22 And a EPS(TTM)=-6,11 This means that the company is losing money. besides that, investors now pay 2,22 Dollars less pr earned dollar They still have a 1,20(8,07%) Forward Dividend and Yield this means that the company is expecting a low grow rate because of the high yield (if the Yield is low, a company is expecting high growth expectations and are more likely to give investors reward through out a rise in the stock price) The Beta is low at 0,72. a Beta below 1 is a less volatile stock. My target will be at 36.49$ where my stops loss will be at 6,18$ general 1y target estimate from other investors is at 20,02$ Profile: Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segment’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products. The company has collaboration arrangements with Attenukine, Procter & Gamble Company, and Regeneron Pharmaceuticals, Inc. (source: finance.yahoo.com) Good luck :)
NYSE:TEVALong
by Fx-AlphaStrats
Portfolio Position: Teva Pharmaceuticals $TEVATeva Pharmaceuticals $TEVA has shed over 50% of its value following its $6.1B impairment charge and 75% dividend slash in its latest quarterly report. Pros: - The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan $AGN. - Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals. - The company is divesting its non-core organic revenue drivers, expected to bring in over $5B in 2017 and boost margins. - Aggressive cost cutting, saving over $1.6B annually is expected to boost Net Income and Margins. Risks: - Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018. - Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price. Targets: I initiate TEVA with a $30 PT for the next 12 months, throughout 2018. For the full review: seekingalpha.com
NYSE:TEVALong
by TraderDanER
GILD Long Due to Rebound, Cheap Prince, Indicators in LineI consider GILD to be a great investment because of various factors: Talking fundamentaly, the company has great numbers and a lot of room to expand. It's free cash flow is stunning and the company is way to big to be bought. Technicaly: As you can see, the MACD, RSI and Stochastic are in line, and ready to go up up up. P/E is at a beautiful 6.95. As you can see in the weekly chart, it's just about to go up. I found a good entry point anywhere between 72 and 73 dolars a share due to support levels. GO BIG OR GO HOME.
NASDAQ:GILDLong
by AngelMB95
LLY Eli Lilly: Where can we buy?This stock has been in a correction for about a year now and it looks like it is not done yet. Looking to the price history on the left we can see that we could soon hit strong support starting from $60.00 which is basically the top of a $48-60 price channel. So I would be looking to buy anywhere below $60 if we re-enter that channel (yellow box). I don't expect price to just move through this channel, just like we cannot just break through a herd of cows crossing the street while driving. In addition, if we copy the move from the swing highs to swing lows from 2015-2016 we can see that an equal move would end right around $60 as well, providing a further reason for entry.
NYSE:LLYLong
by PHL